Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab

INCLUSION CRITERIA

* Males and Females ≥ 18 years old diagnosed with HER2 positive breast cancer
* Scheduled to receive neoadjuvant or adjuvant trastuzumab (Herceptin®) therapy (anthracycline-containing regimens are permitted). Patients receiving Herceptin® with their chemotherapy are permitted for eligibility work-up. Taxanes are permitted. Trastuzumab (Herceptin®) therapy may be given with or after primary chemotherapy. Pertuzumab may be used in conjunction with trastuzumab.
* Left Ventricular Ejection Fraction (LVEF) ≥ 50% by MUGA scan or echocardiogram
* Adequate renal function for administration of trastuzumab-containing chemotherapy regimen.
* Sitting systolic blood pressure of \> 90 mm Hg
* Pulse ≥ 60 beats/minute
* Not pregnant or breastfeeding
* Female patients of childbearing potential, who are sexually active, must have a negative pregnancy test before starting the study
* Both men and women must be willing to use effective contraception during the study. Teratogenicity is documented for both active study agents
* Able to swallow capsules

EXCLUSION CRITERIA:

* Patients with metastatic disease
* Prior treatment with trastuzumab or anthracyclines prior to this chemotherapy regimen
* Current treatment with angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), such as losartan, β-blockers or digoxin
* Known cardiac history: heart failure, myocardial infarction, radiation-induced cardiac dysfunction
* Known allergy to either ACE inhibitors or β-blockers
* History of bronchial asthma or related bronchospastic conditions
* Hereditary or idiopathic angioedema
* History of severe hypersensitivity reactions to drugs or other causes, i.e. bee stings
* This protocol does not exclude patients who are participating on other investigational studies. Refer to the local IRB guidelines.